<DOC>
	<DOC>NCT01238588</DOC>
	<brief_summary>The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).</brief_summary>
	<brief_title>The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Plaque, Atherosclerotic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>A signed consent form; Male or Female, 50 years or older; Diagnosed with end stage renal disease (ESRD), on maintenance hemodialysis for at least three (3) months; On calciumbased phosphate binders; Subject must be able to understand and provide informed consent; No known contraindications to therapy with sevelamer carbonate. Any patient with a medical condition or taking any medications that would be contraindicated with the use of sevelamer carbonate, such as history of bowel obstruction; History of severe allergic reactions to the study medication; History of active infection (other than a simple respiratory tract infection) or acute gouty attack within 2 weeks prior to enrollment; Known serological positivity for Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCV Ab) except dose with normal liver function tests (AST, ALT, Bilirubin, and Alkaline Phophatase) and no history of cirrhosis; Elevation of liver function tests at time of entry (Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) &gt; 2 times the upper limit of normal); History of drug, alcohol, or chemical abuse within 6 months prior to enrollment; History of malignancy except those adequately treated, has completed treatment and clinically in remission for more than 6 month; adequately treated insitu cervical carcinoma, or adequately treated basal or squamous cell carcinoma of the skin; History of an inflammatory disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis or ulcerative colitis except those in remission for more than 6 months; Patients currently on sevelamer carbonate or sevelamer chloride or history of taking them for more than a week in the past three months; Patients receiving chronic antiinflammatory therapy; Patients in whom FDGPET/CT dual scans are contraindicated.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>